

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



WUXI APPTEC CO., LTD.*
無錫藥明康德新藥開發股份有限公司
(the “Company”)

(A joint stock company incorporated in the People’s Republic of China with limited liability)
(Stock Code: 2359)

CHANGE OF CHIEF FINANCIAL OFFICER

The board of directors (the “**Board**”) of the Company hereby announces that on January 18, 2019, the 26th meeting of the first session of the Board has held, at which it has resolved to approve (i) the resignation of Mr. Edward Hu as the chief financial officer of the Company with effect from January 18, 2019; and (ii) the appointment of Mr. Ellis Bih-Hsin Chu as the new chief financial officer of the Company with effect from January 18, 2019.

Mr. Edward Hu tendered his resignation as the chief financial officer for the reason of devoting his effort into the business and internal management of the Company and focusing in his role of co-chief executive officer and executive director of the Company. He will also continue to be a member of the strategy committee of the Company. He has confirmed that he has no disagreement with the Board, nor is there any matter in relation to his resignation as chief financial officer required to be brought to the attention of the shareholders of the Company (the “**Shareholders**”).

The Board would like to take this opportunity to welcome Mr. Ellis Bih-Hsin Chu to serve as the new chief financial officer. Biographical details of Mr. Ellis Bih-Hsin Chu are as follows:

Mr. Ellis Bih-Hsin Chu, aged 48, obtained an MBA degree from Columbia Business School in 2006. Since 2006, he has accumulated over 10 years of experience in investment banking, corporate finance and mergers acquisitions, including serving as an investment banking associate at Lehman Brothers Asia Limited, vice president of Investment Banking at Nomura International (Hong Kong) Limited, director of the Asia IBD-M&A Department at Citigroup Global Markets Asia Limited, managing director and Head of China M&A at Merrill Lynch (Asia Pacific) Ltd and managing director and Head of Greater China at Ion Pacific Limited. Before joining us, he served as the chief financial officer of JHL Biotech Inc. since May 2018.

Mr. Ellis Bih-Hsin Chu did not hold any directorships in any listed public companies in Hong Kong or overseas and he had no relationship with any other directors, senior management, substantial shareholders or controlling shareholder of the Company in the last three years.

As at the date of this announcement, Mr. Ellis Bih-Hsin Chu does not have any interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance.

The term of office of Mr. Ellis Bih-Hsin Chu takes effect from January 18, 2019 until the expiry of the tenure of the members of senior management appointed in the first session of the Board. The remuneration of Mr. Ellis Bih-Hsin Chu as chief financial officer of the Company shall be determined according to the remuneration policy of the Company and factors including his qualifications and experience.

Other than those disclosed herein, there are no other matters in relation to appointment of Mr. Ellis Bih-Hsin Chu which shall be disclosed to the Shareholders and The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) or matters which would require disclosure under rule 13.51(2) of The Rules Governing the Listing of Securities on the Stock Exchange.

By order of the Board
WuXi AppTec Co., Ltd.
Dr. Ge Li
Chairman

Hong Kong, January 18, 2019

As of the date of this announcement, the Board of the Company comprises Dr. Ge Li, Mr. Edward Hu, Mr. Xiaozhong Liu, Mr. Zhaohui Zhang and Dr. Ning Zhao as executive Directors, Mr. Xiaomeng Tong and Dr. Yibing Wu as non-executive Directors and Dr. Jiangnan Cai, Ms. Yan Liu, Mr. Dai Feng, Dr. Hetong Lou and Mr. Xiaotong Zhang as independent non-executive Directors.

* *For identification purpose only*